Corporate news
Extraordinary Shareholders’ Meeting on 19 May 2026
- Corporate news
- Investor relations
Syn2bio now on the stock exchange
- Corporate news
- Investor relations
The division of Synektik is complete – the court has registeredthe issue of Syn2bio shares
- Corporate news
- Investor relations
Synektik shareholders have unanimously approved the division of the company and spinoff of the cardiotracer project to Syn2bio
- Corporate news
- Investor relations
KNF has approved the Syn2bio prospectus. The debut on the WSE is planned for April
- Corporate news
- Investor relations
Synektik edges closer to demerger as Syn2bio files prospectus with KNF
- Corporate news
- Investor relations
Synektik one step closer to planned division
- Corporate news
- Investor relations
Synektik plans to devide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE
- Corporate news
- Investor relations